Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA)

Historical Holders from Q2 2018 to Q3 2025

Symbol
VRCA on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value
Shares outstanding
92.4M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
568
Holdings value
$301
Grand Portfolio weight change
0%
Number of holders
1
Number of sells
-50
Average Value change %
0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Caligan Partners LP 9.99% $7.77M 15.9M Caligan Partners LP 31 Dec 2024
ARMISTICE CAPITAL, LLC 9.99% 0% $7.48M $81.6K 9.24M +1.1% Armistice Capital, LLC 31 Mar 2025
PERCEPTIVE ADVISORS LLC 1.6% -70% $726K -$1.59M 1.48M -68.7% Perceptive Advisors LLC 31 Mar 2025

Institutional Holders of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 568 $301 -$13.3M $0.53 1
2025 Q2 24.7M $13.3M -$2.1M $0.53 52
2025 Q1 29.5M $13M -$1.28M $0.44 72
2024 Q4 30M $21M +$9.29M $0.70 79
2024 Q3 14.8M $21.5M -$32.4M $1.45 77
2024 Q2 18.6M $136M +$6.59M $7.29 73
2024 Q1 17.7M $105M -$1.73M $5.92 61
2023 Q4 18M $132M +$23.7M $7.32 62
2023 Q3 15.1M $58.5M +$1.49M $3.89 66
2023 Q2 14.6M $84.2M +$9.03M $5.77 63
2023 Q1 12.9M $84.2M +$15.1M $6.50 60
2022 Q4 10.8M $29.8M -$1.57M $2.75 49
2022 Q3 10.2M $29.9M -$2.47M $2.92 46
2022 Q2 11.3M $21.7M +$3.2M $1.92 51
2022 Q1 8.88M $72.1M -$553K $8.11 47
2021 Q4 8.95M $82M -$7.32M $9.16 43
2021 Q3 9.17M $115M -$9.41M $12.50 49
2021 Q2 9.94M $112M -$1.69M $11.30 53
2021 Q1 9.93M $150M +$14.7M $15.15 51
2020 Q4 8.96M $103M -$682K $11.51 44
2020 Q3 8.93M $69.1M +$677K $7.74 46
2020 Q2 8.8M $96.9M -$278K $11.01 44
2020 Q1 8.83M $96.5M -$4.77M $10.93 45
2019 Q4 9.2M $144M -$4.09M $15.89 52
2019 Q3 9.27M $137M +$4.18M $14.76 42
2019 Q2 9.02M $105M +$2.58M $11.62 40
2019 Q1 8.82M $97M +$5.66M $10.81 40
2018 Q4 8.45M $68.8M -$1.84M $8.15 41
2018 Q3 8.24M $134M -$2.33M $16.25 45
2018 Q2 8.31M $164M +$164M $19.73 28